niacin Articles
Niacin causes serious unexpected side-effects, but no worthwhile benefits, for at risk patients
11 March 2013
Watson confirms Abbott Niaspan patent challenge
19 March 2012
Abbott Lab’s 4th-quarter 2009 profit flat due to charges, buts sales rise nearly 11% driven by Humira; still open to buys
28 January 2010
Merck & Co remains confident in Zetia and Vytorin, despite studying questioning the drugs
16 November 2009
Merck & Co to roll out Tredaptive by 3rd qtr
20 May 2009
King updates on pain pipeline at APS
11 May 2009
Stock Commentary - New York week to April 20, 2009
23 April 2009
53% jump in 1st-qtr profit for Abbott
15 April 2009
Solvay viewing options for pharma
2 April 2009
Abbott's 4th-qtr profit jumps 28% on strong sales of Humira and divestment of spinal products unit
26 January 2009
Negative press has compromised Vytorin as first-line therapy; DR
17 November 2008
Solvay's 9-month profit down 34% on Fortis
10 November 2008
Solvay's first-half 2008 profit declines 15%
11 August 2008
DR report reveals growing focus on HDL as treatment goal
4 August 2008
Abbott's 2nd qtr results beat expectations
28 July 2008
Potential 5-year delay for US cholesterol pill
30 June 2008
Solvay's 1st-qtr 2008 net income rises 1%
26 May 2008
Generics cut King's 1st-qtr income 16%
19 May 2008
Merck & Co shares fall 5.1% after
5 May 2008
Ph III Acurox trial enrolled
5 May 2008
Abbott reports 35% rise in earnings
28 April 2008
Zetia "could be expensive placebo," ACC hears
7 April 2008
Late-stage Cordaptive trial stalls on IMT issue
7 April 2008
US MDs do not Rx to HLD guidelines
31 March 2008
Abbott gets $100M under Simcor deal
24 March 2008
Abbott's Simcor gets FDA approval as cholesterol control treatment
25 February 2008
Abbott Labs returns to profit in 4th-qtr 2007
28 January 2008
Abbott Labs' 3rd-qtr 2007 net earnings flat
29 October 2007
Solvay to co-promote Abbott's Simcor in USA
29 October 2007
Merck's Cordaptive has positive impact on key lipid parameters
10 September 2007
Peregrine in R&D deal with NIAID
23 July 2007
Abbott Labs' 2nd-qtr 2007 profit soars 61.4%
23 July 2007
Abbott Labs submits US NDA for Simcor
30 April 2007
Stock Commentary - New York week to December 4
11 December 2006
Kos' 3rd-qtr 2006 income rises 17%
27 November 2006
MK-0524 cuts incidence of flushing caused by ERN
27 November 2006
Merck & Co delays 2007 filing of MK-524B on formulation issue, pre-2009 launch unlikely
9 October 2006
Naispan plus statin cost-effective in CVD risk management
2 October 2006
Statins account for 81% of first-line dyslipidemia treatment
30 January 2006
$2M milestone for Arena from Merck & Co deal
1 August 2005
Kos kicks off Niaspin/simvastatin study
18 July 2005
Japan stock market week to June 10
20 June 2005
Barr gets FDA approval for generic Niaspan
9 May 2005
Merck KGaA reports slump in France
11 April 2005
Barr and Kos in settlement talks over Niaspan
4 April 2005
Kos seeks court to block Barr's generic Niaspan
14 March 2005
New schedule for Kos/Barr litigation
1 November 2004
Niacin may protect against Alzheimer's
9 August 2004
Lonza signs niacin production deal with Innovite
2 August 2004
Kos settles with Andrx over Advicor
21 June 2004
Kos takes Barr to court over Niaspin patent
12 April 2004
Merck KGaA/Kos' Niaspan cleared in EU
2 February 2004
Tokyo pharma stocks - week to Nov 10
17 November 2003
Stock Commentary - Tokyo
17 November 2003
Kos and Takeda sign US co-promotion deal
10 November 2003
Sales near flat at Merck KGaA in third qtr, generics grow as pipeline is restructured
3 November 2003
Merck KGaA gets UK approval for Niaspan
23 June 2003
Stock Commentary - New York
23 June 2003
Strong 4th-quarter operating results at Merck KGaA on flat sales
24 February 2003
Kos Pharma sees 1st qtr revenues leap 136%
20 May 2002
Pharma DTC web sites failing to address consumer needs, says study
14 September 2001
Kos Pharma files $200 million shelf offer
3 September 2001
Kos and DuPont file for combo cholesterol drug OK
28 September 2000
Kos/DuPont alliance cleared by FTC
7 June 2000
Kos sees promise with Niaspan in raising HDL
18 May 2000
Kos Pharmaceuticals gets $50 million boost
20 December 1999
Niaspan approved for HDL elevation in USA
4 November 1999
Selecting Diseases Suitable For OTC Treatment
4 December 1998
Kos Files For Niaspan In UK
16 July 1998
Kos/Fuisz File For Once-Daily ISMN
28 April 1998
Kos On Verge Of Generating Revenue
3 September 1997
Kos' Niaspan Cleared In Its First Market
31 July 1997
Scotia Progresses In Schizophrenia
23 April 1997
Scotia Reports Advances In Schizophrenia Therapy
5 August 1996
First Launch Of P&U's Omacor
5 February 1996
NIACIN TOO TOXIC FOR OTC USE
7 March 1994
Showing 1-96 of 96 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
